Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 885 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR An existing blood test for ovarian cancer has been re-evaluated. The... October 28, 2020 Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated... April 13, 2026 Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients... April 7, 2025 Wales: 4 in 10 with possible cancer symptoms didn’t contact GP June 17, 2021 Load more HOT NEWS Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around... Can Having Solar Panels or Living Near a Solar Farm Increase... Withdrawal of the Application to Change the EMA Marketing Authorisation for... We want every scientist to thrive in cancer research
